Overview

A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831

Status:
Completed
Trial end date:
2019-10-30
Target enrollment:
Participant gender:
Summary
This study seeks to evaluate the efficacy and safety of NA-83 in subjects with mild cognitive impairment due to Alzheimer's Disease
Phase:
Phase 2
Details
Lead Sponsor:
NeuroActiva, Inc.
Collaborator:
The Florey Institute of Neuroscience and Mental Health